Skip to main content
Premium Trial:

Request an Annual Quote

Mary Callan Goes from Exelixis to Morphotek; George Milne Joins Athersys Board; Scott Khan Promoted to CSO at Accelrys; and Others

NEW YORK, Feb. 7 -   Mary Callan, former director of business development at Exelixis, has been appointed vice president of business development at Morphotek, the company announced Feb. 5. Morphotek, a privately-owned Philadelphiacompany, conducts directed evolution of microbes for drug discovery and development.


Callan has also served as head of business development at Large Scale Biology Corporation, and has worked in research at BASF.



George Milne, former executive vice president of global R&D at Pfizer, was appointed to Athersys' board of directors, the company announced Feb. 4.  Athersys, of Cleveland, uses its RAGE functional genomics system to express proteins without first cloning and isolating genes, by integrating specialized activation sequences into the genome of the host cell.


Milne recently retired from Pfizer after working at the company in research and management positions since 1970.  He replaces George LeMaitre, head of Bostonarea cardiovascular device company LeMaitre Vascular, who joined Athersys' board of directors in 1995.



Agilent Technologies created a new scientific advisory board, the company said Feb., 4, and appointed to it:


Paul Herring, director of corporate research at Novartis International. Herring is also a professor of drug discovery sciences at the Universityof Basel, Switzerland, and has served in numerous positions in academia and pharma.


Anthony Martin, president and CEO of Molecular Probes. Martin has worked for over 25 years in biotech, most recently serving as president of Invitrogen's molecular biology division.


Mark Skolnick, founder of Myriad Genetics. Skolnick directed the group that cloned several disease-related mutation groups, including the BRCA1 gene for susceptibility to breast cancer, the MMAC1 tumor suppressor gene, the prostate cancer gene HPC2; and also did significant work on p16 and BRCA2.


Wendell Wierenga, CEO of protein structure drug discovery company Syrrx. Wierenga was earlier a senior VP of Parke-Davis/Warner Lambert, which has since been acquired by Pfizer.


The board, which met for the first time earlier this week, is expected to meet two or three times each year.



Scott Kahn has been promoted to chief science officer at Pharmacopeia subsidiary Accelrys, the company said Feb. 3. Khan previously served as general manager and senior vice president of the company's life sciences division.


Before joining Accelrys, Khan was an assistant professor of chemistry at the Universityof Illinois Urbana-Champaign.



Louise Henry has been named vice president, quality, and Mark Enyedy has been named vice president of business development, for Vertex Pharmaceuticals, the company said Feb. 3.

Henry previously served as director of quality operations and quality global product development at Eli Lilly. Enyedy joins Vertex from Genzyme, where he was vice president of business development.


Promoted? Changing jobs? GenomeWeb wants to know. E-mail Marian Jones at [email protected]to appear in PEOPLE, a roundup of personnel comings and goings in genomics, which ordinarily appears every Wednesday.



The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.